He, C., Mi, X., Xu, G., Xu, X., Xin, W., Zhong, L., . . . Ding, H. Cost-effectiveness analysis of tislelizumab plus chemotherapy as the first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma in China. Public Library of Science (PLoS).
Chicago Style (17th ed.) CitationHe, Chaoneng, et al. Cost-effectiveness Analysis of Tislelizumab Plus Chemotherapy as the First-line Treatment for Advanced or Metastatic Oesophageal Squamous Cell Carcinoma in China. Public Library of Science (PLoS).
MLA (9th ed.) CitationHe, Chaoneng, et al. Cost-effectiveness Analysis of Tislelizumab Plus Chemotherapy as the First-line Treatment for Advanced or Metastatic Oesophageal Squamous Cell Carcinoma in China. Public Library of Science (PLoS).
Warning: These citations may not always be 100% accurate.